UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer

European journal of cancer (1990), 2014-06, Vol.50 (9), p.1581-1589

2014

Volltextzugriff (PDF)

COVID-19 and its impact on visitation and management at US national parks

International hospitality review, 2021-12, Vol.35 (2), p.240-259

2021

Volltextzugriff (PDF)

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Cancer treatment reviews, 2016-02, Vol.43, p.67-73

2016

Volltextzugriff (PDF)

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

European journal of cancer (1990), 2015-09, Vol.51, p.S183-S183

2015

Volltextzugriff (PDF)

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-05, Vol.28 (5), p.283-291

2016

Volltextzugriff (PDF)

Vitamin D levels in Swiss breast cancer survivors

Breast (Edinburgh), 2017-03, Vol.32, p.S51-S51

2017

Volltextzugriff (PDF)

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

European journal of cancer (1990), 2015-09, Vol.51, p.S172-S173

2015

Volltextzugriff (PDF)

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S176-S177

2015

Volltextzugriff (PDF)

2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S508-S508

2015

Volltextzugriff (PDF)

Flawed trials for cancer

Annals of oncology, 2020-03, Vol.31 (3), p.331-333

2020

Volltextzugriff (PDF)

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

Annals of oncology, 2015-04, Vol.26 (4), p.750-755

2015

Volltextzugriff (PDF)

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Annals of oncology, 2018-11, Vol.29 (11), p.2200-2207

2018

Volltextzugriff (PDF)

1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time

Annals of oncology, 2023-10, Vol.34, p.S931-S931

2023

Volltextzugriff (PDF)

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Annals of oncology, 2015-04, Vol.26 (4), p.743-749

2015

Volltextzugriff (PDF)

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Annals of oncology, 2013-12, Vol.24 (12), p.2972-2977

2013

Volltextzugriff (PDF)

Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

European urology, 2024-03, Vol.85, p.S1418

2024

Volltextzugriff (PDF)

A0529 - Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

European urology, 2024-03, Vol.85, p.S1418-S1418

2024

Volltextzugriff (PDF)

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

Annals of oncology, 2020-09, Vol.31, p.S961-S961

2020

Volltextzugriff (PDF)

A0535 - Cell-Free DNA genomic profiling and its clinical implementation in advanced prostate cancer

European urology, 2024-03, Vol.85, p.S1424-S1424

2024

Volltextzugriff (PDF)

Cell-Free DNA genomic profiling and its clinical implementation in advanced prostate cancer

European urology, 2024-03, Vol.85, p.S1424

2024

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Volltextzugriff (PDF)

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-04, Vol.30 (4), p.215-224

2018

Volltextzugriff (PDF)

Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer

European urology, 2022-02, Vol.81, p.S633

2022

Volltextzugriff (PDF)

Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review

European urology, 2022-02, Vol.81, p.S840

2022

Volltextzugriff (PDF)

1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Annals of oncology, 2019-10, Vol.30, p.v671-v671

2019

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(65)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer

COVID-19 and its impact on visitation and management at US national parks

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials

Vitamin D levels in Swiss breast cancer survivors

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis

Flawed trials for cancer

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

A0529 - Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade

A0535 - Cell-Free DNA genomic profiling and its clinical implementation in advanced prostate cancer

Cell-Free DNA genomic profiling and its clinical implementation in advanced prostate cancer

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer

Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review

1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Suchergebnisse filtern